Physician profile
Peter Lautenbach
NPI 1447214374
$7,396.82
in general payments reported to CMS, 2019-2025
30 companies · $55.83 in 2025
The $55.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $1,369 · 2021: $1,626 · 2022: $1,077 · 2023: $976 · 2024: $1,000 · 2025: $55.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,519.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $655.62 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $628.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $588.25 | 2019-2024 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $558.40 | 2019-2024 | Xarelto |
| Abbvie INC. | $497.77 | 2021-2025 | |
| Novo Nordisk INC | $384.39 | 2021-2024 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $336.66 | 2019-2024 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $310.70 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $307.24 | 2019-2023 | Seglentis, Livalo |
| Pfizer INC. | $265.85 | 2019-2024 | |
| Amgen INC. | $237.61 | 2019-2024 | Evenity, Prolia |
| Antares Pharma, INC. | $210.09 | 2020-2024 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $166.98 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $160.85 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $72.82 | 2022-2024 | Quviviq |
| Halozyme INC | $51.65 | 2023 | |
| Almatica Pharma LLC | $50.33 | 2022-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $41.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.97 | 2022-2023 | Eliquis |
| Eisai INC. | $23.52 | 2020 | |
| Abbott Laboratories | $21.08 | 2022 | |
| Scilex Pharmaceuticals INC. | $16.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.65 | 2019 | |
| Daiichi Sankyo INC. | $14.37 | 2021 | |
| Sanofi Pasteur INC. | $13.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.30 | 2019 | |
| Corcept Therapeutics | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lautenbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.